Replies to post #160456 on Biotech Values

[oc631]

I don’t think so. The data appear solid enough in GT2 to warrant approval on the current review cycle.

The GT2 data is strong. There also isn't a DAA interferon-based option alternative, both approved and pending approval, for GT2 and GT3 patients (as seen in other genotypes).

GILD's private discussions with the FDA would provide needed clarity.